Missions

Acute myeloid leukemia (AML) and multiple myeloma (MM) are severe hematologic disorders of the bone marrow. Although new therapies have improved patient management, many individuals relapse and become refractory to treatment, highlighting the need for innovative therapeutic approaches.
A promising strategy would be to target genes that are essential for the maintenance of AML/MM but escape mutation-driven changes because they are vital for the survival of transformed cells. This project aims to exploit this (onco)genic dependency by focusing on the gene encoding the transcription factor MYB, a hematopoietic “master regulator” to which AML and MM cells show strong addiction. Through a multidisciplinary consortium combining expertise in epigenetics, clinical research, and chemical engineering, we aim to decipher the regulation of MYB in AML and MM and to develop new therapeutic molecules targeting MYB, with the goal of expanding current clinical options.

Activités

Cellular biology.
Molecular biology.
Cell culture of primary cells from patients.
Plasma cell Différenciation and Multiple Myeloma.
Data analysis.

Compétences

References and letters of recommendation will be requested for the interview. The candidate must demonstrate prior experience in cell culture and molecular biology, preferably in hematology. Rigorous, organized, and dynamic, the candidate should show a strong enthusiasm for science, an excellent team spirit, and the ability to work innovatively and independently.

Contexte de travail

The position is open at the Institute of Human Genetics within the team Epigenome Modifications and Genomic Instability in Normal and Malignant B Cells. This is a 12-month fixed-term contract (CDD), renewable.